For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
15
views
23
references
 Top references
cited by
16
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,436
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated the efficacy of the web based P3P (Personal Patient Profile-Prostate) decision aid vs usual care with regard to decisional conflict in men with localized prostate cancer.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: not found
          • Article: not found

          Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

          Matthew Cooperberg, Peter R. Carroll (2015)
          Article 0 comments Cited 184 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The changing face of prostate cancer.

            Judd W. Moul, Matthew Cooperberg, Peter R. Carroll (2005)
            Prostate cancer remains the most common noncutaneous human malignancy, and the second most lethal tumor among men. However, the natural history of the disease is often prolonged, and the survival benefits of local therapy for men with low-risk tumors may not be realized for a decade or more, as is increasingly well demonstrated in long-term observational cohorts in both the United States and Europe. A significant proportion of men with prostate cancer may be overdiagnosed, in the sense that diagnosis may not improve their lifespan or quality of life. However, the extent to which overdiagnosis represents a true problem relates to the consistency with which diagnosis leads invariably to active treatment. Prostate cancer is diagnosed at progressively earlier stages and with lower risk features; despite these trends, patients are less likely now than a decade ago to undergo a trial of active surveillance. Rates of brachytherapy and hormonal therapy use, in particular, have risen markedly. Important progress has been made in recent years in prostate cancer risk assessment. These advances, in combination with biomarkers in later stages of development, should be expected in the coming years to yield further improvements in clinicians' ability to diagnose prostate cancer early, and guide appropriately selected patients toward increasingly tailored treatment.
            Article 0 comments Cited 58 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions.

              Laura D Scherer, Margaret Holmes-Rovner, Lillie Williamson … (2017)
              To assess the influence of patient preferences and urologist recommendations in treatment decisions for clinically localized prostate cancer.
              Article 0 comments Cited 49 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Journal of Urology
                Abbreviated Title: Journal of Urology
                Publisher: Elsevier BV
                ISSN (Print): 0022-5347
                ISSN (Electronic): 1527-3792
                Publication date Created: January 2018
                Publication date (Print): January 2018
                Volume: 199
                Issue: 1
                Pages: 89-97
                Affiliations
                [1 ]Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, Massachusetts
                [2 ]Department of Urology, Emory University School of Medicine, Atlanta, Georgia
                [3 ]Department of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
                [4 ]Department of Urology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
                [5 ]University of Virginia Schools of Nursing, Charlottesville, Virginia
                [6 ]Department of Urology, School of Medicine, Charlottesville, Virginia
                [7 ]University of Washington School of Nursing, Seattle, Washington
                [8 ]Department of Clinical Pharmacy, University of California-San Francisco, San Francisco, California
                [9 ]Department of Urology, Brigham and Women’s Hospital, Boston, Massachusetts
                [10 ]Department of Urology, University of Massachusetts Memorial Healthcare, Worcester, Massachusetts
                [11 ]Private Practice, Niagara Falls, New York
                Article
                DOI: 10.1016/j.juro.2017.07.076
                PMC ID: 5760348
                PubMed ID: 28754540
                SO-VID: 486ecae6-6b74-43bf-9a56-a484a1697372
                Copyright © © 2018
                License:

                https://www.elsevier.com/tdm/userlicense/1.0/

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content1,436

                See all similar

                Cited by16

                See all cited by

                Most referenced authors206

                See all reference authors